Kvedarienė Violeta, Biliute Gabija, Didziokaitė Gabija, Kavaliukaite Loreta, Savonyte Agne, Rudzikaite-Fergize Gabija, Puronaite Roma, Norkuniene Jolita, Emuzyte Regina, Dubakiene Ruta, Valiulis Arunas, Sousa-Pinto Bernardo, Bedbrook Anna, Bousquet Jean
Department of Pathology, Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania.
Faculty of Medicine, Institute of Clinical Medicine, Clinic of Chest Diseases, Allergology and Immunology, Vilnius University, Vilnius, Lithuania.
Clin Transl Allergy. 2022 Sep;12(9):e12192. doi: 10.1002/clt2.12192.
MASK-air is an app whose aim is to reduce the global burden of allergic rhinitis (AR) and asthma. A transfer of innovative practices was performed to disseminate and implement MASK-air in European regions. The aim of the study was to examine the implementation of the MASK-air app in Lithuanian adults in order to investigate (i) the rate of acceptance in this population, (ii) the duration of app use and (iii) the evaluation of the app after its use.
In a longitudinal study, Lithuanian adults with AR and/or asthma were recruited by allergists. They were informed about how to use MASK-air and were followed closely. They were reviewed after one to 3 months to evaluate satisfaction and were asked to continue using the app.
Among the 149 patients recruited (37.2 ± 10.4 years), 52.4% had rhinitis alone, 42.9% had rhinitis, asthma and/or conjunctivitis multimorbidity, and 2.7% isolated asthma. According to the MASK-air baseline questionnaire, 88.3% of patients considered that their symptoms were troublesome. Data were available for 102 (68.4%) patients. The duration of app usage in patients ranged from 1 to 680 days (median, 25-75 percentile: 54, 23.2-151 days). Forty-two (41.1% of patients who were reviewed) patients agreed to share their opinion on MASK-air . Most users of the app were satisfied, from 46.5% thinking their allergy was treated more successfully to 90.4% recommending this app to other allergy sufferers.
When recommended by physicians, MASK-air® was used for a longer period of time.
MASK-air是一款旨在减轻全球过敏性鼻炎（AR）和哮喘负担的应用程序。为在欧洲各地区推广和应用MASK-air，开展了创新实践的转移。本研究的目的是考察MASK-air应用程序在立陶宛成年人中的应用情况，以调查：（i）该人群的接受率；（ii）应用程序的使用时长；（iii）使用后对该应用程序的评价。
在一项纵向研究中，过敏症专科医生招募了患有AR和/或哮喘的立陶宛成年人。告知他们如何使用MASK-air并对其进行密切跟踪。1至3个月后对他们进行复查以评估满意度，并要求他们继续使用该应用程序。
在招募的149名患者中（年龄37.2±10.4岁），52.4%仅患有鼻炎，42.9%患有鼻炎、哮喘和/或结膜炎合并症，2.7%为单纯哮喘。根据MASK-air基线调查问卷，88.3%的患者认为其症状令人烦恼。102名（68.4%）患者的数据可用。患者应用程序的使用时长为1至680天（中位数，第25 - 75百分位数：54，23.2 - 151天）。42名（接受复查患者的41.1%）患者同意分享他们对MASK-air的看法。该应用程序的大多数用户感到满意，从46.5%认为其过敏治疗更成功到90.4%向其他过敏患者推荐此应用程序。
当由医生推荐时，MASK-air®的使用时间更长。
